Monday, April 18, 2016

BRIEF-Celator pharmaceuticals announces data for Vyxeos for newly diagnosed AML patients

* celator pharmaceuticals announces positive data for

vyxeos in FLT3-ITD mutated acute myeloid leukemia (aml) cells

derived from patients with newly diagnosed AML

Source text for Eikon:

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)